ID: ALA3125368

Max Phase: Preclinical

Molecular Formula: C15H13N3OS

Molecular Weight: 283.36

Molecule Type: Small molecule

Associated Items:

Representations

Canonical SMILES:  Cc1ccc(CSc2nnc(-c3ccncc3)o2)cc1

Standard InChI:  InChI=1S/C15H13N3OS/c1-11-2-4-12(5-3-11)10-20-15-18-17-14(19-15)13-6-8-16-9-7-13/h2-9H,10H2,1H3

Standard InChI Key:  UAXALMYFSXJXSD-UHFFFAOYSA-N

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Small moleculeTopical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Properties

Molecular Weight: 283.36Molecular Weight (Monoisotopic): 283.0779AlogP: 3.73#Rotatable Bonds: 4
Polar Surface Area: 51.81Molecular Species: NEUTRALHBA: 5HBD: 0
#RO5 Violations: 0HBA (Lipinski): 4HBD (Lipinski): 0#RO5 Violations (Lipinski): 0
CX Acidic pKa: CX Basic pKa: 2.48CX LogP: 3.21CX LogD: 3.21
Aromatic Rings: 3Heavy Atoms: 20QED Weighted: 0.68Np Likeness Score: -2.05

References

1. Lukas TJ, Schiltz GE, Arrat H, Scheidt K, Siddique T..  (2014)  Discovery of 1,3,4-oxidiazole scaffold compounds as inhibitors of superoxide dismutase expression.,  24  (6): [PMID:24560539] [10.1016/j.bmcl.2014.01.078]

Source